E. G. Lukyanova

E. G. Lukyanova

Auto-generated profile, based on publicly available information

E. G. Lukyanova

V.F. Voyno-Yasenetsky Scientific and Practical Center of Specialized Medical Care for Children

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2023 in Epilepsy and paroxysmal conditions
Verified
Journal Article
Open access
PDF file
TKTatyana Kozhanova
Tatyana Kozhanova
SZS. S. Zhilina
S. S. Zhilina
TMT. I. Meshcheryakova
T. I. Meshcheryakova
ELE. G. Lukyanova
E. G. Lukyanova
EBE. S. Bolshakova
E. S. Bolshakova
NZNikolay Zavadenko
Nikolay Zavadenko
The article presents the clinical cases of 6 patients with epilepsy, psychomotor and speech developmental delay. The heterozygous variants of the nucleotide sequence in SPTAN1 gene were detected by whole exome sequencing. Mutations in SPTAN1 gene have been described in patients with developmental and epileptic encephalopathy 5 (ОMIM: 613477). The clinical history, electroencephalographic and magnetic resonance imaging data of our patients are similar in children with variants in SPTAN1 gene described previously. It was shown that variants in SPTAN1 gene located closer to the C-terminal region are associated with a more severe phenotype, whereas the variants near the N-region – with a milder course of the disease without structural brain anomalies. However, further research is necessary in the future to better understand genotype-phenotypic correlations in SPTAN1-associated encephalopathy.

27 April 2019 in Epilepsy and paroxysmal conditions
Verified
Journal Article
Open access
PDF file
TKTatyana Kozhanova
Tatyana Kozhanova
SZS. S. Zhilina
S. S. Zhilina
TMT. I. Mescheryakova
T. I. Mescheryakova
ELE. G. Lukyanova
E. G. Lukyanova
KOK. V. Osipova
K. V. Osipova
APA. G. Prityko
A. G. Prityko
The article presents a clinical case of severe infantile generalized idiopathic epilepsy with status-like seizures, muscular dystonia and developmental delay. The examination included a phenotypic analysis: the course of the perinatal period, the nature of seizures, cognitive and behavioral disorders; video electroencephalography, and brain MRI. Using the targeted exome sequencing of genes associated with epileptic encephalopathy (NGS), we detected a nucleotide heterozygous variant of the ALDH7A1 gene (previously not described). This mutation led to the appearance of a stop codon in position 82 of the protein p.Arg82Ter and the amino acid substitution in position 399 of the protein p.Glu399Gln. This clinical observation demonstrates the importance of DNA-based diagnosis involving the targeted exome sequencing to identify molecular defects, especially in severe neonatal drug-resistant seizures. In the case of confirmed mutations in the ALDH7A1 gene, the patient should be given vitamin B6 at the therapeutic doses for seizure relief.

3 October 2022 in Russian neurological Journal
Verified
Journal Article
Closed access
PDF file
EPE. A. Pyr'YEva
E. A. Pyr'YEva
ASA. I. Safronova
A. I. Safronova
MTM. I. Timoshina
M. I. Timoshina
MTM. A. Toboleva
M. A. Toboleva
SAS. O. Aivazyan
S. O. Aivazyan
ELE. G. Luk`yAnova
E. G. Luk`yAnova
Ketogenic diet (KD) refers to promising methods of treatment of epilepsy resistant to anticonvulsants. A clinical case of the use of KD in a child with drug resistant epilepsy (DRE) is presented. This clinical case demonstrates the effectiveness of KD in a child with DRE in the form of achieving 100% control over seizures and positive shifts in the psycho-motor development of the child and positive changes in the child’s psychomotor development while ensuring adequate physical health.

21 July 2021 in Epilepsy and paroxysmal conditions
Verified
Journal Article
Open access
PDF file
APA. G. Prityko
A. G. Prityko
KOK. V. Osipova
K. V. Osipova
PSP. L. Sokolov
P. L. Sokolov
EEE. A. Ezhova
E. A. Ezhova
IKI. G. Kotel’nIkova
I. G. Kotel’nIkova
GOG. A. Osipova
G. A. Osipova
Objective: to confirm a therapeutic equivalence and similar safety profile of “Midazolam, oromucosal (buccal) solution” and “Sibazon, solution for intravenous and intramuscular administration” used in children aged from 1 year to 18 years suffering from primary generalized and bilateral tonic, clonic and tonic-clonic seizures.Material and methods. An open-label, randomized clinical trial on efficacy and safety was conducted with 25 patients having primary generalized and bilateral tonic, clonic and tonic-clonic seizures due to epilepsy or epileptic syndrome. The study used age-appropriate doses of Midazolam with a single buccal administration as well as diazepam (Sibazon) for single intramuscular administration. Midazolam dosing was as follows: 5 mg for children of the younger age group (1 tube-dropper 5 mg/ml), 7.5 mg for children of the middle age group (1 tube-dropper 5 mg/ml and 1 tube-dropper 2.5 mg/ml), 10 mg for older children (2 tube-droppers 5 mg/ml). The drug effectiveness was assessed by primary and secondary criteria. The number of cases of drug administration in each group was used as the primary criteria, in which the convulsions ended up within 10 minutes after using the drug and did not resume within 60 minutes after drug administration. The following criteria were used as secondary: no repeated convulsive seizures within 24 hours after drug administration, no repeated convulsive seizure within 48 hours after drug administration, time before repeated convulsive seizure within 48 hours after drug administration. Clinical assessment was carried out according to clinical data, electroneurophysiologic (electroencephalographic) studies, electrocardiography, clinical blood and urine tests, aswell as biochemical blood tests by measuring glucose, total protein, albumin, total bilirubin, cholesterol, aspartate aminotransferase, alanine aminotransferase, creatine phosphokinase, alkaline phosphatase, creatinine, urea, and creatinine clearance level.Results. Compliance with the first efficacy criterion after using Midazolam and Sibazon was observed in 11 (84.6%) and 9 (75%) patients in Group 1 and Group 2, respectively, showing insignificant differences (Fisher's exact test (FET): p=0.645). The number of no cases of repeated convulsive seizure within 24 hours after drug administration differed significantly and was 12 (92.3%) and 6 (50%), respectively (FET: p=0.030). The number of cases with no second seizures within 48 hours after drug administration in Group 1 and Group 2 was 12 (92.3%) and 5 (41.7%), respectively, showing insignificant differences (FET: p=0.0112). No serious adverse events were reported during the study. No patients cancelled participation in the study due to developed adverse event.Conclusion. The data obtained evidence about compatibility of therapeutic efficacy profile and similar safety profile for “Midazolam, oromucosal (buccal) solution” and “Sibazon, solution for intravenous and intramuscular administration” that agrees with multiple data of earlier studies.

23 April 2021 in Epilepsy and paroxysmal conditions
Verified
Journal Article
Open access
PDF file
TKTatyana Kozhanova
Tatyana Kozhanova
SZS. S. Zhilina
S. S. Zhilina
TMT. I. Meshcheryakova
T. I. Meshcheryakova
ELE. G. Luk’yAnova
E. G. Luk’yAnova
KOK. V. Osipova
K. V. Osipova
NZNikolay Zavadenko
Nikolay Zavadenko
We present the clinical case of patient with epilepsy, developmental retardation and hearing loss. The whole exome sequencing allowed to reveal compound heterozygous variants of the nucleotide sequence in SPATA5 gene (c.1714+1G>A, c.1678G>A). Mutations in the SPATA5 gene have been described in patients with epilepsy, hearing loss and mental retardation syndrome (MIM 616577). Paired parents were carriers of one heterozygous gene variant. Such mutations lead to the development of epileptic disorders in 3% of cases, and should be considered in patients not only as a possible cause of neurodegenerative diseases, but also leading to pathology with clinical manifestations mimicking mitochondrial disease.

16 April 2020 in Epilepsy and paroxysmal conditions
Verified
Journal Article
Open access
PDF file
TKTatyana Kozhanova
Tatyana Kozhanova
SZS. S. Zhilina
S. S. Zhilina
TMT. I. Mescheryakova
T. I. Mescheryakova
ELE. G. Luk`yAnova
E. G. Luk`yAnova
KOK. V. Osipova
K. V. Osipova
APA. G. Prityko
A. G. Prityko
Autism spectrum disorders (ASDs) are a group of complex disintegrative disorders of mental development, characterized by a lack of ability to social interaction, communication, stereotyped behavior, leading to social maladaptation. We present a rare clinical case of a delay in psychomotor and speech development, specific facial dysmorphia, impaired behavior, and a detected mutation in the ADNP gene. When conducting targeted exomic sequencing, we revealed a previously undescribed variant of the nucleotide sequence in the ADNP gene (p.Ala1017fs). Mutations in the ADNP gene in a heterozygous state were described for patients with Helsmoortel-van der Aa syndrome (OMIM: # 615873). Mutations in the ADNP gene are the genetic cause of ASD in 0.17% of cases. When interpreting the data of new generation sequencing (NGS) in patients with epileptic encephalopathy, ASD, and characteristic phenotype, it is advisable to take into account that the ADNP gene is one of the key genes responsible for embryonic neurodevelopment.